A Randomised, 52-week, Treat-to-target Trial Comparing Insulin Detemir with Insulin Glargine when Administered As Add-on to Glucose-lowering Drugs in Insulin-naive People with Type 2 Diabetes

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2008 Jan 22

PMID 18204830

Citations 137

Authors

J Rosenstock

M Davies

P D Home

J Larsen

C Koenen

G Schernthaner

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: This 52-week multinational, randomised, open-label, parallel-group, non-inferiority trial compared clinical outcomes following supplementation of oral glucose-lowering drugs with basal insulin analogues detemir and glargine in type 2 diabetic patients.

Methods: Insulin-naive adults (n=582, HbA(1c) 7.5-10.0%, BMI <or= 40.0 kg/m(2)) were randomised 1:1 to receive insulin detemir or glargine once daily (evening) actively titrated to target fasting plasma glucose (FPG) <or= 6.0 mmol/l. An additional morning insulin detemir dose was permitted if pre-dinner plasma glucose (PG) was >7.0 mmol/l after achieving FPG <7.0 mmol/l. Due to labelling restrictions, no second glargine dose was allowed.

Results: Baseline HbA(1c) decreased from 8.6 to 7.2 and 7.1% (NS) with detemir and glargine, respectively. FPG improved from 10.8 to 7.1 and 7.0 mmol/l (NS), respectively. With detemir, 45% of participants completed the study on once daily dosing and 55% on twice daily dosing, with no difference in HbA(1c). Overall, 52% of participants achieved HbA(1c) <or= 7.0%: 33% (detemir) and 35% (glargine) without hypoglycaemia. Within-participant variability for self-monitored FPG and pre-dinner PG did not differ by insulin treatment, nor did the relative risk of overall or nocturnal hypoglycaemia. Modest reductions in weight gain were seen with detemir vs glargine in completers (3.0 vs 3.9 kg, p=0.01) and in the intention-to-treat population (2.7 vs 3.5 kg, p=0.03), primarily related to completers on once-daily detemir. Mean daily detemir dose was higher (0.78 U/kg [0.52 with once daily dosing, 1.00 U/kg with twice daily dosing]) than glargine (0.44 IU/kg). Injection site reactions were more frequent with detemir (4.5 vs 1.4%).

Conclusions/interpretation: Supplementation of oral agents with detemir or glargine achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia. Non-inferiority was demonstrated for detemir using higher insulin doses (mainly patients on twice daily dosing); weight gain was somewhat reduced with once daily insulin detemir.

Citing Articles

2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.

Moon J, Kang S, Choi J, Lee K, Moon J, Chon S Diabetes Metab J. 2024; 48(4):546-708.

PMID: 39091005 PMC: 11307112. DOI: 10.4093/dmj.2024.0249.

Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review.

Rosenstock J, Bajaj H, Lingvay I, Heller S BMJ Open Diabetes Res Care. 2024; 12(3).

PMID: 38749508 PMC: 11097869. DOI: 10.1136/bmjdrc-2023-003930.

Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.

Dehghani M, Sadeghi M, Barzkar F, Maghsoomi Z, Janani L, Motevalian S Front Endocrinol (Lausanne). 2024; 15:1286827.

PMID: 38586456 PMC: 10997219. DOI: 10.3389/fendo.2024.1286827.

Effectiveness of a Social Networking Site Based Automatic Mobile Message Providing System on Glycemic Control in Patients with Type 2 Diabetes Mellitus.

Kim K, Yun J, Lee J, Yang Y, Lee M, Ahn Y Endocrinol Metab (Seoul). 2023; 39(2):344-352.

PMID: 38148106 PMC: 11066440. DOI: 10.3803/EnM.2023.1871.

7. Diabetes Technology: Standards of Care in Diabetes-2024.

Diabetes Care. 2023; 47(Suppl 1):S126-S144.

PMID: 38078575 PMC: 10725813. DOI: 10.2337/dc24-S007.

References

Home P, Kurtzhals P . Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother. 2006; 7(3):325-43. DOI: 10.1517/14656566.7.3.325. View

Koro C, Bowlin S, Bourgeois N, Fedder D . Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2003; 27(1):17-20. DOI: 10.2337/diacare.27.1.17. View

Heise T, Nosek L, Ronn B, Endahl L, Heinemann L, Kapitza C . Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53(6):1614-20. DOI: 10.2337/diabetes.53.6.1614. View

Turner R, Cull C, Frighi V, Holman R . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281(21):2005-12. DOI: 10.1001/jama.281.21.2005. View

Riddle M . Timely initiation of basal insulin. Am J Med. 2004; 116 Suppl 3A:3S-9S. DOI: 10.1016/j.amjmed.2003.12.003. View

Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K . Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006; 49(3):442-51. DOI: 10.1007/s00125-005-0132-0. View

Wright A, Burden A, Paisey R, Cull C, Holman R . Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002; 25(2):330-6. DOI: 10.2337/diacare.25.2.330. View

Raslova K, Tamer S, Clauson P, Karl D . Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007; 27(4):279-85. DOI: 10.2165/00044011-200727040-00007. View

Riddle M, Rosenstock J, Gerich J . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26(11):3080-6. DOI: 10.2337/diacare.26.11.3080. View

10.

Davies M . The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord. 2004; 28 Suppl 2:S14-22. DOI: 10.1038/sj.ijo.0802745. View

11.

Raslova K, Bogoev M, Raz I, Leth G, Gall M, Hancu N . Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004; 66(2):193-201. DOI: 10.1016/j.diabres.2004.03.003. View

12.

Eliaschewitz F, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J . Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res. 2006; 37(4):495-501. DOI: 10.1016/j.arcmed.2005.10.015. View

13.

Marre M . Before oral agents fail: the case for starting insulin early. Int J Obes Relat Metab Disord. 2002; 26 Suppl 3:S25-30. DOI: 10.1038/sj.ijo.0802174. View

14.

Korytkowski M . When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002; 26 Suppl 3:S18-24. DOI: 10.1038/sj.ijo.0802173. View

15.

Russell-Jones D, Khan R . Insulin-associated weight gain in diabetes--causes, effects and coping strategies. Diabetes Obes Metab. 2007; 9(6):799-812. DOI: 10.1111/j.1463-1326.2006.00686.x. View

16.

Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T . Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007; 9(3):290-9. DOI: 10.1111/j.1463-1326.2006.00685.x. View

17.

Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006; 29(6):1269-74. DOI: 10.2337/dc05-1365. View

18.

Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts V, Thorsteinsson B . Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006; 28(10):1569-81. DOI: 10.1016/j.clinthera.2006.10.020. View

19.

Porcellati F, Rossetti P, Busciantella N, Marzotti S, Lucidi P, Luzio S . Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007; 30(10):2447-52. DOI: 10.2337/dc07-0002. View

20.

Hermansen K, Davies M . Does insulin detemir have a role in reducing risk of insulin-associated weight gain?. Diabetes Obes Metab. 2007; 9(3):209-17. DOI: 10.1111/j.1463-1326.2006.00665.x. View